Project Details
Description
This SRA supports understanding whether Nrf2 agonists may be an important therapeutic target for tissue injury and fibrosis and specifically whether this might be a target in scleroderma.
| Status | Finished |
|---|---|
| Effective start/end date | 12/16/13 → 6/16/16 |
Funding
- Biogen Inc. (Agmt 12/16/13)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.